ConductScience.org, home

Paper35968356

Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.

Tufail M and 2 others. Am J Cancer Res, 2022. Cited by 69 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches. Papers, record 35968356. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35968356

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.
PubMed
Journal
Am J Cancer Res
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
69
iCite
Relative citation ratio, by iCite
5.7
iCite
Revised in PubMed
2022-08-16
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tufail MMuhammad
2Cui JJia
3Wu CChangxin

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References262

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117957337Molecular basis of invasion in breast cancer.Cell Mol Life Sci2007https://conductscience.org/library/papers/17957337PubMed
226122181ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.Nat Rev Clin Oncol2015https://conductscience.org/library/papers/26122181PubMed
37564505Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.Leukemia1995https://conductscience.org/library/papers/7564505PubMed
430867218Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.Clin Cancer Res2019https://conductscience.org/library/papers/30867218PubMed
531548545Breast cancer.Nat Rev Dis Primers2019https://conductscience.org/library/papers/31548545PubMed
62319611Rising incidence of breast cancer: relationship to stage and receptor status.J Natl Cancer Inst1990https://conductscience.org/library/papers/2319611PubMed
725759020Smoothened variants explain the majority of drug resistance in basal cell carcinoma.Cancer Cell2015https://conductscience.org/library/papers/25759020PubMed
827197169The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis.Cancer Res2016https://conductscience.org/library/papers/27197169PubMed
920624968Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/20624968PubMed
1023908178Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.Ann Oncol2013https://conductscience.org/library/papers/23908178PubMed
1121876693Targeting the tumor microenvironment: focus on angiogenesis.J Oncol2012https://conductscience.org/library/papers/21876693PubMed
1228073840FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma.Clin Cancer Res2017https://conductscience.org/library/papers/28073840PubMed
1328888902A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.Osteoarthritis Cartilage2018https://conductscience.org/library/papers/28888902PubMed
1416530045Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA.Cell2006https://conductscience.org/library/papers/16530045PubMed
1516862189Drug penetration in solid tumours.Nat Rev Cancer2006https://conductscience.org/library/papers/16862189PubMed
1610742152Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.Nat Med2000https://conductscience.org/library/papers/10742152PubMed
1711895119Chemistry and chemical biology of taxane anticancer agents.Chem Rec2001https://conductscience.org/library/papers/11895119PubMed
1823509322Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.J Clin Oncol2013https://conductscience.org/library/papers/23509322PubMed
1935328602Drug Metabolism for the Identification of Clinical Biomarkers in Breast Cancer.Int J Mol Sci2022https://conductscience.org/library/papers/35328602PubMed
2022019144Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.Lancet2011https://conductscience.org/library/papers/22019144PubMed

See all 262 referencesDownload CSV of references

Cited by48

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.

PMIDTitleJournalYearIn PapersSource
42802225Hereditary breast cancer: emerging roles of non-coding RNAs.Hereditas2026https://conductscience.org/library/papers/42802225PubMed
42701436Enhanced anticancer efficacy of Pa-MAP 1.9 peptide-coated silver nanostars on breast cancer cells.Mater Today Bio2026https://conductscience.org/library/papers/42701436PubMed
42489715Liposomes-enabled gemcitabine therapy for breast cancer: in vitro and in vivo studies.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/42489715PubMed
42405118Advances in the design and discovery of small-molecule tyrosine kinase inhibitors for breast cancer.RSC Adv2026https://conductscience.org/library/papers/42405118PubMed
42370136L-arginine metabolism in breast cancer: mechanisms and therapeutic targets.Front Oncol2026https://conductscience.org/library/papers/42370136PubMed
42218186Novel pyridine-based chalcone analogs and triple negative breast cancer: potential therapy & molecular pathways.Sci Rep2026https://conductscience.org/library/papers/42218186PubMed
42180128Breast cancer chemotherapy in transition: predictive markers, resistance mechanisms, and new treatment approaches.Front Oncol2026https://conductscience.org/library/papers/42180128PubMed
42032115An in vitro hydrogel-based model to study dormancy associated drug resistance in metastatic breast cancer spheroids.NPJ Biomed Innov2025https://conductscience.org/library/papers/42032115PubMed
41971420Breast cancer pathogenesis, diagnosis and treatment: a comprehensive review.Front Oncol2026https://conductscience.org/library/papers/41971420PubMed
41888569A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind.Mol Syst Biol2026https://conductscience.org/library/papers/41888569PubMed
41828663Design and Multi-Level Biological Evaluation of Naphthyridine-Based Derivatives as Topoisomerase I/II-Targeted Anticancer Agents with Anti-Fowlpox Virus Activity Supported by In Silico Analysis.Int J Mol Sci2026https://conductscience.org/library/papers/41828663PubMed
41516029
Potential Anticancer Effect of Cannabis sativa L. Dichloromethane Extract Through Oxidative Stress-Related Pathways and the Inhibition of the Migration and Invasiveness of Human Breast Cancer Cells (MDA-MB-231 and MCF-7).
Int J Mol Sci2025https://conductscience.org/library/papers/41516029PubMed
41236673Decoding breast cancer: insights into molecular pathways & therapeutic approaches.Discov Oncol2025https://conductscience.org/library/papers/41236673PubMed
41234888Identification of molecular subtypes for breast cancer based on butyrate metabolism-related genes to assess prognosis and immune landscape.Transl Cancer Res2025https://conductscience.org/library/papers/41234888PubMed
41171336Research progress of DUB enzyme in breast cancer.Clin Exp Med2025https://conductscience.org/library/papers/41171336PubMed
41098828Strategies for the drug development of cancer therapeutics.Front Pharmacol2025https://conductscience.org/library/papers/41098828PubMed
41050699HLA-DR expression in cytotoxic T lymphocytes: a key to boost the therapeutic potential of T cell-based strategies for breast cancer.Front Immunol2025https://conductscience.org/library/papers/41050699PubMed
40745071Targeting iron regulatory protein 2 (IRP2) to disrupt iron metabolism enhances radiosensitivity through mitochondrial dysfunction in breast cancer cells.Cell Death Discov2025https://conductscience.org/library/papers/40745071PubMed
40586858Liquid biopsy in breast cancer: clinical implications of ctDNA and CTCs in diagnosis, treatment and monitoring.Mol Cell Biochem2025https://conductscience.org/library/papers/40586858PubMed
40519297PLCH1 overexpression promotes breast cancer progression and predicts poor prognosis through the ERK1/2-EGR1 axis.Front Oncol2025https://conductscience.org/library/papers/40519297PubMed

See all 48 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35968356

GET https://conductscience.org/api/papers/v1/35968356/references?page=2